Five things for pharma marketers to know: Thursday, May 24, 2018
Recro non-opioid injection receives complete response letter from FDA; Pfizer settles False Claims Act allegations; Medtronic reports better-than-expected profit.
How data regulation could be good for marketing post-Cambridge Analytica
Stuart Ingis on the benefits of showing the public how advertisers and marketers use data and creating a global regulatory framework.
4As O'Brien: How healthcare marketing has changed under Trump
Speakers at the Coalition for Healthcare Communication conference discussed how regulations from the White House and FDA have affected healthcare comms.
Health diagnostic startup Nanobiosym brings on Finn Partners as AOR
Nanobiosym hired the agency shortly after its proprietary technology was approved by the FDA.
MM&M Hall of Femme 2018: The profiles
MM&M is honoring 15 of the most-senior women in healthcare along with 20 Women to Watch who are changing the industry.
Plan D: Experts predict government savings, but higher co-pays with Trump plan for lowering drug prices
The White House's strategy calls for moving expensive treatments from under Medicare Part B to Medicare Part D.
Experts skeptical feds' move on Insys will tilt scales of justice against opioid maker
Insys founder John Kapoor has maintained his innocence in the face of charges.
Accenture Interactive launches programmatic unit in response to 'significant' client demand
Accenture has taken another big step into the agency space by launching a programmatic media planning and buying unit.
Five things for pharma marketers to know on Wednesday, May 23, 2018
Keytruda passes late-stage trial; Astellas to cut 600 jobs in restructuring; Teva expects FDA decision on migraine drug by mid-September.
Five things for pharma marketers to know: Tuesday, May 22, 2018
Geisinger looks to expand DNA sequencing program; Celgene invests $65 million more in Evotec; Oscar launches transparency push.
'300' director Zack Snyder takes Leukemia & Lymphoma Society campaign in bolder direction
The Beating Cancer Is in Our Blood brand positioning was developed with Oberland.
Five things for pharma marketers to know: Monday, May 21, 2018
FDA approves AstraZeneca potassium drug; Nabriva pneumonia treatment meets Phase III endpoints; "Bad Blood" hits bookshelves.
Meet the 2018 Women to Watch Honorees
MM&M is honoring 20 Women to Watch, aspiring healthcare commercial and marketing execs changing the face of the industry.
Five things for pharma marketers to know: Friday, May 18, 2018
First preventative migraine treatment approved; NIH investigates funding for alcohol study; Trump to block federal funding for abortion clinics.
How Amazon's culture fuels innovation
Shaun Qualheim from Amazon Web Services explained how the company's small teams and customer-first and failure-friendly culture promotes innovation.
'When we look at health we have to unpack emotion': More soundbites from Transforming Health
Experts on using technology to change patient behavior and other topics.
